Palacaparib

Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer. It is a selective PARP1 inhibitor.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1375173256 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.